Acadian Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Acadian Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,223	Closed	-$47K	–	2105
2021 Q2	$47K	Sell	14,223 -18,372	-56%	-$59K	﹤0.01%	1811
2021 Q1	$123K	Buy	+32,595	New	+$142K	﹤0.01%	1627

Other funds holding BLCM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Acadian Asset Management's BLCM Position: Q3 2021 in Review

Acadian Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2021, closing a stake of 14,223 shares — an estimated $47K sold.

Acadian Asset Management first reported a position in BLCM in Q1 2021 and held it in 2 quarters. The position peaked at $123K in Q1 2021. 28 funds tracked by Wall St. Rank hold BLCM as of Q3 2021.

Acadian Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Acadian Asset Management sold 14,223 Bellicum Pharmaceuticals, Inc. shares in Q3 2021, an estimated $47K.
Acadian Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
Acadian Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $123K in Q1 2021.
28 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2021.

Based on Acadian Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.